US drug giant Pfizer just announced that it is buying cancer biotech Array BioPharma for about $11 billion. Pfizer has been betting heavily that new cancer drugs will be key to its future growth. The latest deal marks a shift for the company into two new, important areas: the skin cancer melanoma and colorectal cancers that start in the colon or rectum.  Click here for more BI Prime stories.

US drug giant Pfizer, which has been charting an expansion into cancer, just struck a deal to buy...

Continue Reading Pfizer just struck an $11 billion deal, and it marks an ambitious shift in the US drug giant's blockbuster cancer strategy